Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2Gliosarcoma 2Glioma 2Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Medulloblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms, Male 1Adenocarcinoma 1

Interventions

Temozolomide 13Filgrastim 8Carboplatin 8Radiotherapy 7Magnetic Resonance Spectroscopy 7Etoposide 7Cisplatin 7Cyclophosphamide 6Bevacizumab 6Vincristine 4Thiotepa 4Carmustine 4sargramostim 3Surveys and Questionnaires 3Peripheral Blood Stem Cell Transplantation 3Methotrexate 3Lapatinib 3Irinotecan 3Azacitidine 3veliparib 2alovudine 2aldesleukin 2Tamoxifen 2Radiotherapy, Conformal 2Radiation 2Paclitaxel 2Mental Status and Dementia Tests 2Imatinib Mesylate 2Granulocyte-Macrophage Colony-Stimulating Factor 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ependymoma × 1-methyltryptophan × Clear all
NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡